Epigenetic Regulation of the Expression of T Cell Stimulatory and Inhibitory Factors by Histone H3 Lysine Modification Enzymes and Its Prognostic Roles in Glioblastoma-Reference-Cited by-同舟云学术

Epigenetic Regulation of the Expression of T Cell Stimulatory and Inhibitory Factors by Histone H3 Lysine Modification Enzymes and Its Prognostic Roles in Glioblastoma

Published:2023 Issue:33 Volume:38 Page:
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Lee Sang Hyuk¹^ORCID,Kim Seung Hwan¹^ORCID,Nam Taek Min¹^ORCID,Jang Ji Hwan¹^ORCID,Kim Kyu Hong¹^ORCID,Lee Young-Sam²³^ORCID,Kim Minseok S.²⁴^ORCID,Kim Mee-Seon⁵^ORCID,Jin Sung Yup⁶^ORCID,Lee Moonok⁶^ORCID,Lee Sung-Hun⁷^ORCID,Kim Young Zoon¹^ORCID

Affiliation:

1. Department of Neurosurgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.

2. Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology, Daegu, Korea.

3. Well Aging Research Center, Division of Biotechnology, Daegu Gyeongbuk Institute of Science and Technology, Daegu, Korea.

4. Translational Responsive Medicine Center, Daegu Gyeongbuk Institute of Science and Technology, Daegu, Korea.

5. Department of Pathology, School of Dentistry, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea.

6. Department of Anesthesiology and Pain Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.

7. Cancer Research Institute, Clinomics Inc., Suwon, Korea.

Funder

National Research Foundation of Korea

Sungkyunkwan University

Samsung Changwon Hospital

Publisher

XMLink

Subject

General Medicine

Link

https://jkms.org/pdf/10.3346/jkms.2023.38.e258

Reference68 articles.

1. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015

2. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

3. An Updated Nationwide Epidemiology of Primary Brain Tumors in Republic of Korea, 2013

4. MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma

5. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial